Thus, we provided compelling evidence demonstrating that the m6A reader IGF2BP3 contributes to tumorigenesis and poor prognosis in AML and can serve as a target for the development of cancer therapeutics. This evidence concerns the gene IGF2BP3 and acute myeloid leukemia.